Loading...
Market
What will be the impact on Stryker's market share in the peripheral vascular segment by end of 2025?
2
Resolution / Starting Odds
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Industry reports and market analysis publications
Story
Stryker to Acquire Inari Medical for $4.9 Billion at $80/Share, Focusing on VTE Treatments
Jan 6, 2025, 09:09 PM
Stryker Corp. has announced a definitive agreement to acquire Inari Medical, Inc. for $80 per share in cash, valuing the deal at approximately $4.9 billion. This acquisition will allow Stryker to expand its offerings into the high-growth peripheral vascular segment, focusing on venous thromboembolism (VTE) treatments. Inari's innovative product portfolio, which includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism, complements Stryker's existing Neurovascular business. The transaction is expected to close by the end of the first quarter of 2025, pending customary closing conditions including regulatory approvals.
View original story
Similar markets
20% to 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
More than 30% • 25%
Modified Terms • 25%
Completed • 25%
Delayed • 25%
Cancelled • 25%
No • 50%
Yes • 50%
Neutral • 25%
Positive • 25%
Unchanged • 25%
Negative • 25%
Yes • 50%
No • 50%
1 new competitor • 25%
3 or more new competitors • 25%
2 new competitors • 25%
No new competitors • 25%
2 major competitors • 25%
1 major competitor • 25%
No major competitors • 25%
3 or more major competitors • 25%
Less than 20% • 25%
More than 60% • 25%
41% to 60% • 25%
20% to 40% • 25%
10% to 15% • 25%
More than 15% • 25%
5% to 10% • 25%
Less than 5% • 25%
26% to 50% • 25%
Less than 10% • 25%
More than 50% • 25%
10% to 25% • 25%
20-30% • 25%
More than 30% • 25%
Less than 10% • 25%
10-20% • 25%
Zepbound gains >10% market share over Wegovy • 25%
Wegovy maintains current market share • 25%
Wegovy gains market share over Zepbound • 25%
Zepbound gains 0-10% market share over Wegovy • 25%